Antimetabolite pathway enzyme

Antimetabolite pathway enzymes are a diverse group of proteins essential for the biosynthesis of DNA and RNA, making them critical therapeutic targets in oncology and immunology (StatPearls, 2023). These enzymes, including dihydrofolate reductase (DHFR), thymidylate synthase (TS), and ribonucleotide reductase (RNR), facilitate the production of purine and pyrimidine nucleotides required for cellular replication (NIH, 2022). Antimetabolite drugs are structural analogs of natural metabolites that competitively inhibit these enzymes or are incorporated into nucleic acids, leading to DNA damage and apoptosis (American Cancer Society, 2024). Because cancer cells exhibit high rates of proliferation and nucleotide demand, they are particularly sensitive to the disruption of these metabolic pathways (Longdom, 2024). However, the lack of absolute specificity often results in toxicities in rapidly dividing healthy tissues, such as the bone marrow and gastrointestinal tract (Drugs.com, 2024). Clinical management frequently involves genetic testing for enzymes like TPMT or DPYD to optimize dosing and minimize adverse effects (PubMed, 2021).

Other names

Antimetabolite targetsNucleotide metabolism enzymesDNA synthesis enzymesFolate pathway enzymesPyrimidine synthesis enzymesPurine synthesis enzymes

Antimetabolites act as structural analogs of natural metabolites (such as purines, pyrimidines, or folic acid) and competitively inhibit key enzymes in the nucleotide biosynthetic pathways. This inhibition leads to the depletion of essential DNA/RNA precursors or the incorporation of fraudulent nucleotides into nucleic acid strands, resulting in DNA damage, inhibition of replication, and induction of apoptosis (StatPearls, 2023; NIH, 2022).